hotspot -WSS

hotspot

author：leisure time 2025-09-29 02:30:26 Page View：95763

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： People with substance use disorder deserve online privacy
Next article： In Memoriam: Notable people who died in 2023

knowledge

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

White House Covid adviser calls on docs to combat misinformation

AshishJha,coordinatoroftheWhiteHouseCovidresponseteamBRENDANSMIALOWSKI/AFPviaGettyImagesWALTHAM,Mass

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

Gene therapy denied for Afghan refugee whose father aided U.S.

ThePashaichildren(fromleft):Abubakar,Mohammad,andSufyan.Illustration:STAT;PhotoCourtesyOnasweltering

hotspot

focus

knowledge

Gene therapy denied for Afghan refugee whose father aided U.S.